HDAC inhibitors cause site-specific chromatin remodeling at PU.1-bound enhancers in K562 cells

BACKGROUND: Small molecule inhibitors of histone deacetylases (HDACi) hold promise as anticancer agents for particular malignancies. However, clinical use is often confounded by toxicity, perhaps due to indiscriminate hyperacetylation of cellular proteins. Therefore, elucidating the mechanisms by wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Frank, Christopher L., Manandhar, Dinesh, Gordân, Raluca, Crawford, Gregory E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4833939/
https://www.ncbi.nlm.nih.gov/pubmed/27087856
http://dx.doi.org/10.1186/s13072-016-0065-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4833939/
https://www.ncbi.nlm.nih.gov/pubmed/27087856
http://dx.doi.org/10.1186/s13072-016-0065-5

Ejemplares similares